IP Library Patent Application 13356073
Patent Application
App. No. 13/356,073

GENERATION OF PHOTORECEPTORS FROM HUMAN RETINAL PROGENITOR CELLS USING POLYCAPROLACTONE SUBSTRATES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/356,073
Abstract

The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

Claims (29)

1 . A biocompatible composition comprising:

a biodegradable polyester carrier film, the surface of said film being micro-textured, and

a layer of isolated and substantially homogenous undifferentiated human retinal progenitor cells adhered to at least a portion of the surface of said polyester film,

wherein said undifferentiated cells are capable of differentiating into photoreceptor cells.

2 . The composition of claim 1 wherein the polyester is selected from the group consisting of polylactic acid (PLA), polycaprolactone (PCL), polyesteramide (PEA), polyhydroxybutyrate (PHB), and derivatives and mixtures thereof.

3 . The composition of claim 1 wherein the polyester is polycaprolactone (PCL).

4 . (canceled)

5 . (canceled)

6 . The composition of claim 1 wherein the differentiated photoreceptor cells are transplanted into a host.

7 . The composition of claim 1 wherein the differentiated photoreceptor cells are used for drug discovery and testing.

8 . The composition of claim 1 wherein the differentiated photoreceptor cells are cultured in the presence of at least one exogenous growth factor.

9 . The composition of claim 3 which is a biocompatible scaffold for human retinal transplantation into a human eye.

10 . The composition of claim 1 wherein a coating of is applied to the polyester film surface prior to depositing human retinal progenitor cells onto the film.

11 . The composition of claim 10 wherein the coating is a material selected from the group consisting of poly-D-lysine, poly-L-lysine, fibronectin, laminin, collagen I, collagen IV, vitronectin, matrigel, and mixtures thereof.

12 . The composition of claim 1 wherein the retinal progenitor cells are obtained from post-natal retinal tissue.

13 . The composition of claim 1 wherein the retinal progenitor cells are obtained from the fetal neural retina.

14 . The composition of composition 1 wherein the polyester film has a thickness in the range of from about 1.0 μm to about 10 μm, and preferably about 5 μm.

15 . The composition of claim 1 wherein the layer of cells is a monolayer.

16 . (canceled)

17 . The composition of claim 1 wherein the texture is in the form of a series of micro-grooves.

18 . The composition of claim 1 wherein the texture is in the form of a series of micro-posts.

19 . A method for drug discovery comprising

contacting a candidate drug target with human retinal progenitor cells obtained in claim 4 ,

evaluating the interaction of the drug target with said cells, and

selecting a viable drug candidate based on said interaction.

20 . The method of claim 19 wherein said interaction involves enhanced proliferation and/or differentiation of said retinal progenitor cells.

21 . A method for treatment of a diseased or degenerated human retina in a patient comprising transplanting the composition of claim 3 into a sub retinal space of a human eye to thereby replace or repair photoreceptor cells in said patient.

22 . The method of claim 21 wherein the diseased or degenerative condition is selected from the group consisting of retinis pigmentosa, age related macular degeneration, traumatic optic neuropathy and retina detachment.

23 . The method of claim 21 wherein the diseased or degenerative condition is age related macular degeneration.

Assignments (2)
LICENSE Recorded Sep 17, 2018
From: THE SCHEPENS EYE RESEARCH INSTITUTE
To: RENEURON LIMITED
Reel/Frame 047099/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2012
From: REGATIERI, CAIO; BARANOV, PETR Y.; YOUNG, MICHAEL J.
To: THE SCHEPENS EYE RESEARCH INSTITUTE
Reel/Frame 027687/0810 →